Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment entities : Cns pharmaceuticals, inc. save search
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2024-01-17 (Crawled : 14:30) - biospace.com/
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 5.82%
H: 7.57%
C: -7.32%
berubicin treatment pharmaceuticals glioblastoma study
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
Published: 2023-12-06 (Crawled : 17:00) - biospace.com/
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 0.0%
H: 8.02%
C: -0.94%
cure cancer treatment pharmaceuticals
Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals’ Innovative Approach To Treatment Could Offer Hope
Published: 2023-10-16 (Crawled : 23:00) - biospace.com/
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 4.44%
H: 21.2%
C: 14.89%
cure hope treatment glioblastoma
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: -2.8%
H: 18.26%
C: 13.46%
rapid berubicin treatment ongoing glioblastoma study
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-08-03 (Crawled : 12:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.07%
H: 0.83%
C: 0.57%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 0.93%
H: 3.24%
C: 1.39%
berubicin update treatment ongoing pharmaceuticals trial glioblastoma study
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-05-25 (Crawled : 20:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.18%
H: 0.79%
C: -2.78%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: -4.52%
H: 6.84%
C: 4.74%
berubicin treatment pharmaceuticals glioblastoma study
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-04-10 (Crawled : 16:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.23%
H: 1.81%
C: 1.25%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: -4.79%
H: 8.16%
C: 4.9%
berubicin treatment 100 glioblastoma study
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2023-04-06 (Crawled : 14:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.79%
H: 0.86%
C: 0.6%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 53.58%
H: 6.02%
C: -43.6%
approval berubicin treatment pharmaceuticals global trial
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
Published: 2023-03-09 (Crawled : 14:20) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -2.68%
H: 5.52%
C: 3.54%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: -2.72%
H: 4.3%
C: -5.59%
treatment ongoing pharmaceuticals global trial berubicin momentum switzerland
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2023-02-07 (Crawled : 14:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.0%
H: 0.64%
C: -0.91%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: -1.49%
H: 5.19%
C: -6.49%
treatment ongoing pharmaceuticals global trial berubicin
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Published: 2022-12-08 (Crawled : 15:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.34%
H: 1.98%
C: -1.85%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 2.92%
H: 0.03%
C: -3.66%
treatment ongoing pharmaceuticals trial berubicin glioblastoma
CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-11-02 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.72%
H: 4.93%
C: 0.24%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 5.88%
H: 15.28%
C: 11.0%
treatment ongoing pharmaceuticals global trial berubicin
CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM
Published: 2022-10-07 (Crawled : 12:20) - globenewswire.com
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: -4.1%
H: 14.38%
C: 7.0%
treatment europe pharmaceuticals broadcast trial berubicin
CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-09-28 (Crawled : 13:20) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.2%
H: 9.44%
C: 6.58%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: -4.79%
H: 9.94%
C: 7.79%
treatment europe ongoing pharmaceuticals global trial berubicin
CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-09-23 (Crawled : 14:00) - biospace.com/
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: -0.31%
H: 6.32%
C: 0.95%
treatment ongoing pharmaceuticals global study glioblastoma
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-06-23 (Crawled : 13:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.09%
H: 3.99%
C: 3.0%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 32.07%
H: 1.89%
C: -24.85%
treatment fda ongoing trial approval berubicin potential
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.2%
H: 0.68%
C: -0.26%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 8.65%
H: 0.0%
C: -6.34%
treatment approval berubicin potential glioblastoma
CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-06 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.09%
H: 1.8%
C: 0.45%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 5.16%
H: 7.69%
C: 6.16%
treatment approval berubicin potential glioblastoma
CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-05 (Crawled : 14:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.63%
H: 1.09%
C: -2.15%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 0.24%
H: 29.56%
C: 14.4%
treatment approval berubicin switzerland potential glioblastoma
CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2021-12-02 (Crawled : 15:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.27%
H: 3.46%
C: -5.38%
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 10.38%
H: 0.0%
C: -8.55%
treatment approval berubicin potential switzerland glioblastoma
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TRMK 4 | $29.89 1.81% 2.7K
|
Finance
TSHA | $2.375 1.06% 19K
|
Health Technology
TSN | $61.57 0.41% 14K
|
Consumer Non-Durables
TMUS S | $164.61 0.26% 190K
|
Communications
TTEC 4 | $8.02 1.5K
|
Commercial Services
TRMB S | $59.26 -0.42% 9.8K
|
Electronic Technology
AMED | $90.65 -0.44% 3.1K
|
Health Services
TRS 4 | $26.08 -0.76% 1K
|
Producer Manufacturing
TRV | $211.8 -0.76% 21K
|
Finance
TT | $294.15 -0.79% 21K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.